Established rheumatoid arthritis. The pathogenic aspects

Publication date: Available online 27 January 2020Source: Best Practice &Research Clinical RheumatologyAuthor(s): Serena Bugatti, Emanuele Bozzalla Cassione, Ludovico De Stefano, Antonio ManzoAbstractThe development of rheumatoid arthritis (RA), at least in its autoantibody-positive subset, evolves through a series of events starting well before the appearance of synovitis. The distinction between ‘early’ and ‘established’ RA is, therefore, an evolving concept. In routine practice, however, the management of RA still starts with the occurrence of clinically detectable synovitis. As such, the synovial membrane remains a major target for the exploitation of possible stage-specific drivers of the disease. The recognition of a ‘window of opportunity’, in which treatment is more likely to succeed, raises the hypothesis that there might be a period in which the biological processes of RA are less mature and potentially reversible. The present review aims to provide a general picture of the modifications occurring in RA synovium, analysing the contribution of both infiltrating immune cells and stromal cells. When available, differences between early and established RA will be discussed.
Source: Best Practice and Research Clinical Rheumatology - Category: Rheumatology Source Type: research

Related Links:

Authors: Conti P, Gallenga CE, Tetè G, Caraffa A, Ronconi G, Younes A, Toniato E, Ross R, Kritas SK Abstract SARS-CoV-2, also referred to as CoV-19, is an RNA virus which can cause severe acute respiratory diseases (COVID-19), with serious infection of the lower respiratory tract followed by bronchitis, pneumonia and fibrosis. The severity of the disease depends on the efficiency of the immune system which, if it is weak, cannot stem the infection and its symptoms. The new CoV-19 spreads in the population at a rate of 0.8-3% more than normal flu and mostly affects men, since immune genes are more expressed o...
Source: Journal of Biological Regulators and Homeostatic Agents - Category: Biomedical Science Tags: J Biol Regul Homeost Agents Source Type: research
In this study (Trial Registration Number: IRCT2017100213739N10), 12 RA patients (according to the American College of Rheumatology criteria) and 12 healthy subjects (as control group) were selected. The gene expression of miR-146a, IRAK1, TRAF6, and NF-κB were measured at the baseline and after 12 weeks M2000 therapy, using quantitative real-time PCR method. Moreover, the serum levels of IL-6 and TNF-α were evaluated at the similar times by ELISA method.Results: Our findings showed that the gene expression of miR-146a, IRAK1, TRAF6, and NF-κB significantly decreased after 12 weeks M2000 ther...
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
This report provides an in-depth look at public drug program spending in Canada, using the Canadian Institute for Health Information's (CIHI) National Prescription Drug Utilization Information System. Public drug program spending does not include spending on drugs dispensed in hospitals or on those funded through cancer agencies and other special programs. Public drug program spending increased by 6.8% in 2018, compared to an increase of 5.3% in 2017. The growth in 2018 was largely because of the introduction of Ontario Health Insurance Plan+ (OHIP+), which extended drug coverage to all Ontario residents age 24 years or y...
Source: Healthcare Quarterly - Category: International Medicine & Public Health Source Type: research
In the original article, the corresponding author ’s given name and middle name were interchanged.
Source: Rheumatology International - Category: Rheumatology Source Type: research
Radiopharmaceutical developer Navidea Biopharmaceuticals has inked a letter...Read more on AuntMinnie.comRelated Reading: Navidea gets 5-year patent extension for Lymphoseek Navidea raises $7.6M, regains listing compliance Navidea claims victories in legal case with former CEO Navidea signs immunotherapy deal with IMV Navidea highlights rheumatoid arthritis results
Source: Headlines - Category: Radiology Source Type: news
Collagen vascular disease, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and scleroderma (SSc), all have auto-antibodies in their pathogenesis though the effect after heart transplantation is not known. Our aim was to assess the impact of collagen vascular disease on the risk of post-transplant donor specific antibodies (DSA), rejection, and cardiac allograft vasculopathy (CAV).
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (598) Source Type: research
ConclusionIntense dust cloud exposure among responders and PTSD among community members were associated with a statistically significant increased risk of new ‐onset systemic autoimmune disease. Clinicians treating 9/11 survivors should be aware of the potential increased risk of systemic autoimmune disease in this population.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
Sanofi and Regeneron Pharmaceuticals Inc have expanded a clinical trial of their rheumatoid arthritis drug Kevzara as a coronavirus treatment to patients outside the United States.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news
(Reuters)—Sanofi and Regeneron Pharmaceuticals Inc. have expanded a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a coronavirus treatment to patients outside the U.S. The companies said enrolments for the mid-to-late stage trial of sarilumab, an immune-system modifying drug known as a monoclonal antibody, have now started in Italy, Spain, Germany, France, Canada... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Drug Updates clinical trials COVID-19 Regeneron Pharmaceuticals Inc. Sanofi sarilumab Source Type: research
More News: Arthritis | Rheumatoid Arthritis | Rheumatology